News of Note—Dynavax’s Heplisav-B, Emergent outlook and more

non
In this week's News of Note, Dynavax has launched its hepatitis B vaccine Heplisav-B in the U.S.

Here's some other vaccine news of note for the week:

> As GlaxoSmithKline and Merck & Co. face supply issues that have led to global hepatitis B vaccine shortage, Dynavax has launched its recently approved Heplisav-B in the U.S. at the wholesale acquisition price of $115 per dose, or $230 per regimen. Release

> Emergent BioSolutions announced its 2018 financial guidance. It expects full-year revenues of $715 million to $755 million, up from the just amended 2017 preliminary results of between $555 million and $560 million. Release

> The WHO prequalified the first typhoid conjugate vaccine, Typbar-TCV, manufactured by India’s Bharat Biotech, making the vaccine eligible for international procurement. The vaccine can be given to young children and has longer-lasting immunity than older versions. WHO Release

> A new study published in The Lancet found PharmaJet’s needle-free injection technology could augment Zika DNA vaccine immune responses. The Lancet study